Related Experiment Videos
Regression of structural cardiovascular changes by antihypertensive therapy
Insights
Antihypertensive therapy can control cardiac hypertrophy in spontaneously hypertensive rats (SHR) by normalizing blood pressure. Drug-specific effects and treatment timing influence outcomes, potentially preventing cardiac dysfunction.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Research
Background:
- Left ventricular (LV) hypertrophy is a cardiac adaptation to chronic pressure overload.
- Spontaneously hypertensive rats (SHR) serve as a model for genetically determined hypertension.
Purpose of the Study:
- To investigate the effects of antihypertensive agents on cardiac hypertrophy in SHR.
- To explore drug-specific modulations and timing of therapy on cardiac structure and function.
Main Methods:
- Treatment of SHR with various antihypertensive agents (e.g., hydralazine, captopril, metoprolol, nifedipine).
- Assessment of blood pressure normalization, LV hypertrophy, collagen concentration, and LV function.
- Comparison of single versus combined drug therapies and treatment timing (preventive vs. established hypertrophy).
Main Results:
- Long-term blood pressure normalization effectively controlled cardiac hypertrophy.
- Combined therapy (metoprolol + hydralazine) resulted in lower LV hypertrophy than single hydralazine, despite equal blood pressure reduction.
- Preventive therapy prevented cardiac dysfunction; therapy for established hypertrophy showed varied effects on collagen concentration.
- LV function improved with antihypertensive therapy in cases of LV dilatation and increased systolic wall stress, but not in concentric hypertrophy with normal wall stress.
Conclusions:
- Antihypertensive therapy is crucial for managing cardiac hypertrophy and preventing cardiac dysfunction in hypertensive models.
- The choice of agent and timing of intervention significantly impact therapeutic outcomes.
- LV systolic unloading via antihypertensive therapy can improve cardiac function in specific conditions like LV dilatation.
Abstract:
Left ventricular (LV) hypertrophy is the structural adaptation of the heart in response to chronic LV pressure load. Studies in spontaneously hypertensive rats (SHR), which represent a model of genetically determined arterial hypertension, reveal that cardiac hypertrophy can be controlled by long-term blood pressure normalization with the use of various antihypertensive agents, such as arterial vasodilatators (hydralazine), converting enzyme inhibitors (captopril), beta-receptor blockers (metoprolol), antiadrenergic substances (alpha-methyldopa, guanethidine), and calcium antagonists (nifedipine, felodipine). Additional drug-specific effects modulate the mechanical effect of LV systolic unloading on cardiac hypertrophy: after a combined treatment with metoprolol and hydralazine, LV hypertrophy was quantitatively lower than after single hydralazine therapy, although blood pressure had been lowered to the same extent. LV collagen concentration remained unchanged when medical treatment prevented the development of myocardial hypertrophy. However, when therapy was begun after hypertrophy had been completely established, reversal of hypertrophy was associated with an increased LV collagen concentration. In concentric LV hypertrophy with normal systolic wall stress, LV function was not impaired. Consequently, antihypertensive therapy could not improve LV function in this condition. However, in the case of LV dilatation with increased systolic wall stress, LV systolic unloading by antihypertensive therapy could considerably improve LV pumping function. Preventive studies reveal that chronic blood pressure control can prevent cardiac dysfunction in SHR, as frequently is seen in the later phase of untreated arterial hypertension in humans.